Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Nat Med Retrieve available abstracts of 18 articles: HTML format Text format

Single Articles

June 2018
1. GUO X, Zhang Y, Zheng L, Zheng C, et al
   Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.
   Nat Med. 2018 Jun 25. pii: 10.1038/s41591-018-0045.
   PubMed     Text format     Abstract available
   
   
   
2. THOMMEN DS, Koelzer VH, Herzig P, Roller A, et al
   A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.
   Nat Med. 2018 Jun 11. pii: 10.1038/s41591-018-0057.
   PubMed     Text format     Abstract available
   
   
   
3. LISSANU DERIBE Y, Sun Y, Terranova C, Khan F, et al
   Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.
   Nat Med. 2018 Jun 8. pii: 10.1038/s41591-018-0019.
   PubMed     Text format     Abstract available
   
   
   May 2018
4. MAINARDI S, Mulero-Sanchez A, Prahallad A, Germano G, et al
   SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
   Nat Med. 2018 May 28. pii: 10.1038/s41591-018-0023.
   PubMed     Text format     Abstract available
   
   
   April 2018
5. ROBICHAUX JP, Elamin YY, Tan Z, Carter BW, et al
   Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
   Nat Med. 2018 Apr 23. pii: 10.1038/s41591-018-0007.
   PubMed     Text format     Abstract available
   
   
   March 2018
6. DARDAEI L, Wang HQ, Singh M, Fordjour P, et al
   SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
   Nat Med. 2018 Mar 5. pii: nm.4497. doi: 10.1038/nm.4497.
   PubMed     Text format     Abstract available
   
   
   October 2017
7. ROMERO R, Sayin VI, Davidson SM, Bauer MR, et al
   Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
   Nat Med. 2017 Oct 2. doi: 10.1038/nm.4407.
   PubMed     Text format     Abstract available
   
   
   August 2017
8. XUE Y, Martelotto L, Baslan T, Vides A, et al
   An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
   Nat Med. 2017;23:929-937.
   PubMed     Text format     Abstract available
   
   
   July 2017
9. MAYORCA-GUILIANI AE, Madsen CD, Cox TR, Horton ER, et al
   ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix.
   Nat Med. 2017;23:890-898.
   PubMed     Text format     Abstract available
   
   
   June 2017
10. RICKMAN DS, Beltran H, Demichelis F, Rubin MA, et al
    Biology and evolution of poorly differentiated neuroendocrine tumors.
    Nat Med. 2017;23:1-10.
    PubMed     Text format     Abstract available
    
    
    February 2017
11. CHUANG CH, Greenside PG, Rogers ZN, Brady JJ, et al
    Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis.
    Nat Med. 2017 Feb 13. doi: 10.1038/nm.4285.
    PubMed     Text format     Abstract available
    
    
    November 2016
12. CARTER L, Rothwell DG, Mesquita B, Smowton C, et al
    Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer.
    Nat Med. 2016 Nov 21. doi: 10.1038/nm.4239.
    PubMed     Text format     Abstract available
    
    
    March 2016
13. OXNARD GR
    The cellular origins of drug resistance in cancer.
    Nat Med. 2016;22:232-4.
    PubMed     Text format    
    
    
    
14. AMBROGIO C, Gomez-Lopez G, Falcone M, Vidal A, et al
    Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.
    Nat Med. 2016;22:270-7.
    PubMed     Text format     Abstract available
    
    
    
15. HATA AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, et al
    Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
    Nat Med. 2016;22:262-9.
    PubMed     Text format     Abstract available
    
    
    February 2016
16. DU Y, Yamaguchi H, Wei Y, Hsu JL, et al
    Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Nat Med. 2016;22:194-201.
    PubMed     Text format     Abstract available
    
    
    November 2015
17. GAO H, Korn JM, Ferretti S, Monahan JE, et al
    High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
    Nat Med. 2015;21:1318-25.
    PubMed     Text format     Abstract available
    
    
    
18. WANING DL, Mohammad KS, Reiken S, Xie W, et al
    Excess TGF-beta mediates muscle weakness associated with bone metastases in mice.
    Nat Med. 2015;21:1262-71.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: